Uncategorized

Zimmer Biomet expects the massive effort to shift its entire U.S. salesforce to a more specialized, direct approach will help it better compete in the orthopedics market.

Moderna claimed that the decision, issued by top vaccine regulator Vinay Prasad, was “inconsistent” with prior FDA communications and went against the regulator’s established guidance for flu shots.

A recurring theme Tuesday morning at Phacilitate’s Advanced Therapies Week was the quickly emerging potential of in vivo approaches to cell and gene therapy—a trend also reflected in recent investments by Eli Lilly and Regeneron.

Last month, biopharmas let go or projected they would let go of less than 500 people combined, based on BioSpace estimates, down almost 1,000 from January 2025. Still, competition for open jobs remains strong, with employed and unemployed biotech and pharma professionals eyeing their next roles.

The subpoenas request additional documents and information from CVS, Centene, Elevance and more, and suggest House Republicans are considering legislation to combat what they view as rampant fraud in the ACA exchanges.

The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third quarter of 2025.

The Taiwan-based company is establishing a manufacturing center for the U.S. market.

A nadie le gusta pasar hambre, y a las células cancerosas tampoco. En un nuevo estudio se ha descubierto que, ante la falta de glucosa, las células tumorales reaccionan liberando una proteína, denominada LIF, que aumenta la agresividad de la invasión tumoral. El estudio, …

After receiving a letter directly from CBER Director Vinay Prasad, Moderna said the FDA had previously signed off on the use of a licensed flu vaccine as a comparator for a Phase 3 study of mRNA-1010.

The percentage of patients achieving total clearance of eczema lesions in a Phase 2b trial increased with prolonged rezpeg treatment.